MOTS-c: The Tiny Mitochondrial Peptide That Behaves Differently in Health and Cancer

Deep inside every human cell, mitochondria are best known as the furnaces that burn nutrients to generate ATP. But over the past decade, researchers have come to appreciate that these organelles are also secretory signaling hubs, releasing chemical messages encoded in their own genome that travel to the nucleus and even to distant tissues. One of the most intriguing of these messages is MOTS-c, a peptide of just 16 amino acids encoded within the mitochondrial 12S ribosomal RNA region. A new review published in the Journal of Translational Medicine by Weina Kong, Yadong Yin, Shuhua Zhao, Boyi Ma, Ziting Chen, Jia Xi, and senior author Hong Yang of Air Force Medical University and Xi’an Jiaotong University synthesizes what is now known about this mitochondria-derived peptide and arrives at a central conclusion: MOTS-c is not simply a beneficial stress-protective hormone, but a context-dependent signal whose effects flip depending on cell type, metabolic state, inflammatory environment, and disease setting.

The story of MOTS-c began with the recognition that the mitochondrial genome, long assumed to encode only 13 proteins of the oxidative phosphorylation machinery plus tRNAs and rRNAs, harbors short open reading frames that yield functional peptides. MOTS-c, whose name derives from “mitochondrial open reading frame of the 12S rRNA type-c,” emerged as a representative member of this expanding family of mitochondrial-derived peptides, which also includes humanin and the small humanin-like peptides SHLP1 through 6. Structurally, MOTS-c is unusual: it is rich in methionine and basic residues, and it can translocate to the nucleus, where it acts directly on chromatin, a property that distinguishes it from most circulating peptide hormones and gives it a uniquely intimate connection to gene regulation.

At the mechanistic level, the review lays out a coherent signaling framework. In the cytosol, MOTS-c can activate the AMP-activated protein kinase, or AMPK, a master energy sensor, partly through accumulation of AICAR, an intermediate of the purine synthesis pathway that MOTS-c helps generate from folate cycle metabolites. AMPK activation in turn suppresses the mechanistic target of rapamycin complex 1, mTORC1, shifting cells from an anabolic, growth-oriented state toward a catabolic, stress-adaptive one. In the nucleus, MOTS-c interacts with transcription factors and chromatin-modifying machinery, including the transcription factor ATF4-dependent integrated stress response and, in some settings, the antioxidant transcription factor Nrf2, driving the expression of genes bearing antioxidant response elements. These pathways converge on redox control, promoting the activity of enzymes such as superoxide dismutase, catalase, heme oxygenase-1, and NAD(P)H quinone dehydrogenase 1, thereby buffering reactive oxygen species and stabilizing cellular homeostasis under metabolic stress.

The physiological repertoire attributed to MOTS-c is remarkably broad. The review catalogs reported roles in exercise adaptation, where MOTS-c levels rise with physical activity and the peptide appears to contribute to muscle metabolic remodeling and thermogenesis through pathways involving PGC-1α and uncoupling proteins. It details protective effects in models of diet-induced obesity and insulin resistance, where MOTS-c administration improves glucose tolerance and lipid profiles. It also covers endothelial protection, suppression of inflammatory signaling through the NF-κB and NLRP3 inflammasome axes, regulation of apoptosis via the Bcl-2 and Bax balance, and benefits in preclinical models of chronic kidney disease, osteoporosis, and cardiopulmonary bypass injury. In each of these contexts, the peptide behaves as a homeostatic buffer, helping cells and tissues adapt to metabolic and oxidative stress rather than succumbing to it.

Yet the clinical evidence is strikingly heterogeneous, and the authors devote considerable attention to why. Measurements of circulating MOTS-c abundance in human cohorts have produced inconsistent results, with some studies reporting lower levels in type 2 diabetes, obesity, or coronary artery disease, and others finding elevated or unchanged concentrations. The review identifies plausible biological and methodological culprits: assay variability between enzyme-linked immunosorbent assay kits and mass spectrometry, the short half-life and rapid clearance of the peptide, the influence of age, sex, body mass index, and circadian rhythms, and the fact that circulating MOTS-c may not reflect intracellular or intramitochondrial pools that could be the functionally decisive fraction. Without standardized detection methods and agreed-upon reference compartments, the authors argue, the true relationship between MOTS-c abundance and human disease remains an open question.

The most provocative section of the review concerns cancer, where the context-dependence of MOTS-c becomes starkest. In some tumor models, MOTS-c acts as a suppressor: it can promote apoptosis of cancer cells, sensitize them to chemotherapy, and restrain epithelial-mesenchymal transition through modulation of pathways involving YAP, STAT3, and TGF-β. The peptide has also been implicated in promoting ferroptosis, the iron-dependent form of cell death, by influencing glutathione metabolism, the cystine transporter SLC7A11, and the GPX4 axis, offering a potential route to undermine the redox resilience that tumors depend upon.

In other contexts, however, the same peptide appears to work in the tumor’s favor. The review describes evidence that MOTS-c can contribute to metabolic reprogramming that supports tumor cell survival, help cancer cells adapt to oxidative stress, remodel the tumor microenvironment through effects on cancer-associated fibroblasts and extracellular matrix deposition, and modulate immune cell populations, including regulatory T cells and dendritic cells, in ways that may blunt antitumor immunity. There are also indications that MOTS-c signaling may contribute to therapeutic resistance, potentially through mechanisms involving multidrug resistance transporters, enhanced stress granule formation, and activation of survival kinases such as AKT and ERK. The authors are careful to frame this evidence as emerging and still limited, but the conceptual implication is clear: a signal that protects normal cells from stress can, under the altered selection pressures of malignancy, protect tumor cells from the very therapies designed to kill them.

This duality is not a contradiction but a lesson in biological context. The review emphasizes that MOTS-c’s action is shaped by subcellular localization, since nuclear MOTS-c reprograms gene expression while cytosolic and mitochondrial pools may act locally; by cell type, since stromal and immune cells in the tumor microenvironment may respond differently from epithelial cancer cells; by the metabolic state of the tissue, since AMPK and mTOR signaling are interpreted differently in nutrient-replete versus nutrient-deprived conditions; and by the inflammatory milieu, since the same redox-buffering activity that quells damaging inflammation in chronic disease may also shield tumor cells from oxidative attack by immune cells. Any therapeutic strategy that delivers MOTS-c systemically, or blocks it indiscriminately, would therefore need to account for which compartment and which cell population is being targeted.

The authors close with a research agenda that reads like a checklist for the field’s maturation. Priority tasks include establishing standardized, quantitative detection methods for MOTS-c in plasma, tissues, and subcellular fractions; mapping the trafficking routes that carry the peptide from mitochondria to nucleus and into the circulation; identifying the full set of molecular targets and binding partners in a cell-specific manner; and dissecting the effects of MOTS-c separately in tumor cells and in the stromal and immune compartments of the microenvironment. Only with that granularity, they argue, can the field determine in which disease contexts boosting MOTS-c signaling would be therapeutically beneficial and in which it could be detrimental.

For a 16-amino-acid peptide discovered barely a decade ago, MOTS-c has traveled an extraordinary conceptual distance, from metabolic curiosity to a candidate mediator of exercise, aging, inflammation, and cancer biology. The review’s central message is a caution against hype in either direction: MOTS-c is neither a universal elixir of metabolic health nor a straightforward oncogene. It is a stress signal, and like all stress signals, its meaning depends entirely on who is listening, under what conditions, and to what end. As mitochondria continue to shed their reputation as mere power plants, MOTS-c stands as a vivid example of how much biology remains encoded in the small, overlooked corners of the human genome, and how carefully that biology must be read before it is exploited in the clinic.

Subject of Research: The mitochondria-derived peptide MOTS-c as a context-dependent stress signal in metabolic homeostasis and cancer

Article Title: MOTS-c: a context-dependent mitochondrial stress signal in homeostasis and tumor

Article References: Kong, W., Yin, Y., Zhao, S., Ma, B., Chen, Z., Xi, J., & Yang, H. (2026). MOTS-c: a context-dependent mitochondrial stress signal in homeostasis and tumor. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09029-6

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09029-6

Keywords: MOTS-c, mitochondrial-derived peptide, mitochondrial signaling, AMPK, oxidative stress, inflammation, tumor microenvironment, ferroptosis, metabolic homeostasis, cancer biology, therapeutic resistance, mitochondrial genome